CTOs on the Move

Boston MicroFluidics

www.bostonmicrofluidics.com

 
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Boston MicroFluidics raised $17.5M on 08/27/2019

Similar Companies

Georgia Assoc. for Primary Health Care

Georgia Assoc. for Primary Health Care is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ardian

Ardian is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

All Care Visiting Nurse Association Of Greater Lynn Inc

All Care Visiting Nurse Association Of Greater Lynn Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lynn, MA. To find more information about All Care Visiting Nurse Association Of Greater Lynn Inc, please visit www.allcarevna.org

Tacoma Radiology

Tacoma Radiology is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Tacoma, WA. To find more information about Tacoma Radiology, please visit www.tramedicalimaging.com

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.